What does Adverum do?

Adverum Biotechnologies is a clinical-stage gene therapy company based in Redwood City, California. Founded in 2012, the company focuses on developing innovative therapies for prevalent ocular diseases, particularly wet age-related macular degeneration (wet AMD). Adverum aims to establish gene therapy as a new standard of care, with the goal of restoring vision and preventing blindness. The company's lead product, ixoberogene soroparvovec (Ixo-vec), is an investigational one-time gene therapy designed to treat neovascular (wet) AMD. Utilizing a proprietary adeno-associated virus (AAV) vector platform, Ixo-vec transforms retinal cells into "biofactories" that produce aflibercept, potentially extending treatment benefits and reducing the need for frequent injections. Adverum also develops therapies for rare conditions, such as blue-cone monochromacy, through its advanced AAV vector technology. The company was acquired by Eli Lilly and Company in 2025, marking a significant partnership in its mission to address serious ocular diseases.